<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; lobbyists</title>
	<atom:link href="http://www.tapanray.in/tag/lobbyists/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Shifting Pharma Supply Chain Strategy From Global To Local</title>
		<link>http://www.tapanray.in/shifting-pharma-supply-chain-strategy-from-global-to-local/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=shifting-pharma-supply-chain-strategy-from-global-to-local</link>
		<comments>http://www.tapanray.in/shifting-pharma-supply-chain-strategy-from-global-to-local/#comments</comments>
		<pubDate>Mon, 08 Jun 2020 00:00:14 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[chain]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[export]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[lobbyists]]></category>
		<category><![CDATA[local]]></category>
		<category><![CDATA[logistics]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Pharmacy]]></category>
		<category><![CDATA[Procurement]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reevaluating]]></category>
		<category><![CDATA[shifting]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Supply]]></category>
		<category><![CDATA[supply-chain]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[top]]></category>
		<category><![CDATA[United States]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[vulnerability]]></category>
		<category><![CDATA[Vulnerable]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10120</guid>
		<description><![CDATA[Alongside large-scale disruptions of many critical industrial operations, Covid-19 global pandemic took the wind out of the sail of pharma supply chain, as well, at the very onset of lockdowns. This happened in many countries around the world, including the &#8230; <a href="http://www.tapanray.in/shifting-pharma-supply-chain-strategy-from-global-to-local/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/shifting-pharma-supply-chain-strategy-from-global-to-local/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Will ‘Patent Thicket’ Delay Biosimilar Drug Entry in India?</title>
		<link>http://www.tapanray.in/will-patent-thicket-delay-biosimilar-drug-entry-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=will-patent-thicket-delay-biosimilar-drug-entry-in-india</link>
		<comments>http://www.tapanray.in/will-patent-thicket-delay-biosimilar-drug-entry-in-india/#comments</comments>
		<pubDate>Mon, 22 Apr 2019 00:00:21 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[3d]]></category>
		<category><![CDATA[ABBvie]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[Cyltezo]]></category>
		<category><![CDATA[delay]]></category>
		<category><![CDATA[demand]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[entry]]></category>
		<category><![CDATA[evergreening]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Humira]]></category>
		<category><![CDATA[incremental]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPO]]></category>
		<category><![CDATA[linkage]]></category>
		<category><![CDATA[lobbyists]]></category>
		<category><![CDATA[Losec]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[nexium]]></category>
		<category><![CDATA[Office]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Prilosec]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[section]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Thicket]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9496</guid>
		<description><![CDATA[Do pharma and biotech investors encourage companies indulging in ‘patent thicket?’ This question recently grabbed media headlines. On April 02, 2019, one such report brought out: AbbVie investors are calling for the Chair-CEO power split, flagging the CEO’s USD 4 million bonus payout, fueled &#8230; <a href="http://www.tapanray.in/will-patent-thicket-delay-biosimilar-drug-entry-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/will-patent-thicket-delay-biosimilar-drug-entry-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
